# US 2015/0147411 A1 · Composition for preventing or treating colitis comprising s-allyl-l-cysteine as active ingredient, and medical preparation comprising same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147411 A1
- Document ID: US20150147411A1
- Status: Published application
- Kind: A1
- Application number: 14/412,674
- Filed: 2013-07-03
- Published: 2015-05-28
- Earliest claimed: 2012-07-03
- Assignees: Pharmaking Co., Ltd.
- Applicants: Pharmaking Co., Ltd.
- Inventors: Soon Bae Kim; Gwang Soon Kim; Wan Bae Kim; Wie Jong Kwak; Sun Duck Jeon; Hyung Young Yoon; Ki Baik Hahm; Eun Hee Kim
- Web page: https://patentgrep.com/patent/US20150147411A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61M 15/009: {using medicine packages with incorporated spraying means, e.g. aerosol cans (pocket atomiser of the injector type A61M11/08)}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 39/06: Free radical scavengers or antioxidants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a composition for preventing or treating colitis. According to one embodiment of the present invention, the composition for preventing or treating colitis comprises S-allyl-L-cysteine, a pharmaceutically acceptable salt thereof, or a solvate or hydrate of the same as an active ingredient, and exhibits an anti-inflammatory action in colitis. The composition for preventing or treating colitis has outstanding effects in preventing and alleviating colitis due to the effect of the anti-inflammatory action and the effect of an antioxidant action of S-allyl-L-cysteine, while at the same time S-allyl-L-cysteine is not accompanied by side-effects, therefore, has a wide scope of use against colitis.

## Claims

### Claim 1

A composition for preventing or treating colitis, comprising S-allyl-L-cysteine, a pharmaceutically acceptable salt thereof, or a solvate or hydrate thereof as an active ingredient.

### Claim 2 (depends on 1)

The composition of claim 1, wherein S-allyl-L-cysteine is obtained by isolation and purification from the plant Allium genus, by synthesis, or by fermentation.

### Claim 3 (depends on 1)

The composition of claim 1, further comprising an anti-inflammatory agent or an anti-oxidant agent.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the anti-inflammatory agent is selected from the group consisting of ibuprofen, ketoprofen, flurbiprofen, feno-profen, naproxen, piroxicam, tenoxicam, isoxicam, melo-xicam, indomethacin, aceclofenac, diclofenac, and a combination thereof, and the anti-oxidant agent is selected from the group consisting of vitamin A, vitamin C, vitamin E, carotenoid, zinc, copper, iron, manganese, lutein, zeaxanthin, selenium, glutathione (GSH), lycopene, and a combination thereof.

### Claim 5 (depends on 1)

A medicinal formulation, comprising the composition of claim 1, the medicinal formulation being selected from the group consisting of an oral dosage form, a mucosal application, an injection, an inhaler, and an external application.

### Claim 6 (depends on 2)

A medicinal formulation, comprising the composition of claim 2, the medicinal formulation being selected from the group consisting of an oral dosage form, a mucosal application, an injection, an inhaler, and an external application.

### Claim 7 (depends on 3)

A medicinal formulation, comprising the composition of claim 3, the medicinal formulation being selected from the group consisting of an oral dosage form, a mucosal application, an injection, an inhaler, and an external application.

### Claim 8 (depends on 4)

A medicinal formulation, comprising the composition of claim 4, the medicinal formulation being selected from the group consisting of an oral dosage form, a mucosal application, an injection, an inhaler, and an external application.
